Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Biotech
Health
STAT+
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Pharmalot
STAT+

Dozens of hospitals slashed use of two key heart drugs after price hikes

  • Ed Silverman

By Ed Silverman Aug. 10, 2017

Reprints
Intravenous drips childhood cancer
APStock

Early last year, a former Valeant Pharmaceuticals (VRX) executive told Congress that, when the company took huge price hikes on two life-saving heart drugs in 2013, the drug maker believed the move “should not reduce patient access.”

He was wrong.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Ed Silverman

Ed Silverman

Pharmalot Columnist, Senior Writer

Ed Silverman covers the pharmaceutical industry.

Tags

New lupus partnership with FDA aims to end drug…
New lupus partnership with FDA aims to end drug trials’ history of failure
Cases of Marburg going unreported in Equatorial Guinea, WHO…
Cases of Marburg going unreported in Equatorial Guinea, WHO says
The lab leak conversation shows it’s time to rethink…
The lab leak conversation shows it’s time to rethink our biosecurity infrastructure, not just policies
Dutch health minister won’t cover a Gilead cancer drug…
Dutch health minister won’t cover a Gilead cancer drug due to the cost
NIH releases data showing more clinical trial sponsors are…
NIH releases data showing more clinical trial sponsors are reporting results, but most miss deadlines
New lupus partnership with FDA aims to end drug…
New lupus partnership with FDA aims to end drug trials’ history of failure

Recommended Stories